UK Markets close in 2 hrs 5 mins
  • FTSE 100

    6,676.92
    -38.50 (-0.57%)
     
  • FTSE 250

    20,628.27
    -165.45 (-0.80%)
     
  • AIM

    1,190.74
    -7.35 (-0.61%)
     
  • GBP/EUR

    1.1226
    -0.0055 (-0.49%)
     
  • GBP/USD

    1.3658
    -0.0072 (-0.5258%)
     
  • BTC-GBP

    23,757.68
    +1,553.14 (+6.99%)
     
  • CMC Crypto 200

    643.85
    +33.86 (+5.55%)
     
  • S&P 500

    3,853.07
    +1.22 (+0.03%)
     
  • DOW

    31,176.01
    -12.37 (-0.04%)
     
  • CRUDE OIL

    51.79
    -1.34 (-2.52%)
     
  • GOLD FUTURES

    1,841.10
    -24.80 (-1.33%)
     
  • NIKKEI 225

    28,631.45
    -125.41 (-0.44%)
     
  • HANG SENG

    29,447.85
    -479.91 (-1.60%)
     
  • DAX

    13,860.80
    -45.87 (-0.33%)
     
  • CAC 40

    5,543.51
    -47.28 (-0.85%)
     

Migraine Pipeline Review, H2 2020: Therapeutics Development & Assessment, Drug Profiles, Dormant Projects, Discontinued Products, Development Milestones, Competitive Landscape

Research and Markets
·3-min read

Dublin, Dec. 23, 2020 (GLOBE NEWSWIRE) -- The "Migraine - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Migraine - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Migraine (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Migraine (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 2, 8, 18, 12, 1, 32, 6 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 3 molecules, respectively.

Migraine (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Migraine (Central Nervous System).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Migraine (Central Nervous System) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

Introduction

Migraine - Overview

Migraine - Therapeutics Development

Migraine - Therapeutics Assessment

Migraine - Companies Involved in Therapeutics Development

Migraine - Drug Profiles

Migraine - Dormant Projects

Migraine - Discontinued Products

Migraine - Product Development Milestones

Appendix

Companies Mentioned

  • 4P Therapeutics LLC

  • Acadia Pharmaceuticals Inc

  • Achelios Therapeutics Inc

  • Acorda Therapeutics Inc

  • AgoneX Biopharmaceuticals Inc

  • Allergan Ltd

  • Allodynic Therapeutics LLC

  • Amgen Inc

  • AOBiome LLC

  • Aptarion biotech AG

  • Asarina Pharma AB

  • Assertio Therapeutics Inc

  • Astrocyte Pharmaceuticals Inc

  • Avanir Pharmaceuticals Inc

  • Axsome Therapeutics Inc

  • Better Life Pharmaceuticals Inc

  • Biogen Inc

  • Biohaven Pharmaceutical Holding Company Ltd

  • Blackthorn Therapeutics Inc

  • Cerecin Inc

  • Charleston Laboratories Inc

  • Citragen Pharmaceuticals Inc

  • Corium Inc

  • Crossject SA

  • Curatis AG

  • CURx Pharmaceuticals Inc

  • DelNova Inc

  • Eli Lilly and Co

  • Epalex Corp

  • Exxel Pharma Inc

  • H. Lundbeck AS

  • Impel NeuroPharma Inc

  • InKemia IUCT Group SA

  • InStar Technologies AS

  • IntelGenx Corp

  • Invisio Ltd

  • Ionis Pharmaceuticals Inc

  • Kissei Pharmaceutical Co Ltd

  • Klaria Pharma Holding AB

  • Lateral Pharma Pty Ltd

  • Living Cell Technologies Ltd

  • MannKind Corp

  • Medytox Inc

  • Merck & Co Inc

  • NAL Pharmaceuticals Ltd

  • NeurAxon Pharma Inc

  • NeuroPharm Inc

  • NutriBand Inc

  • OWP Pharmaceuticals Inc

  • Panaxia Pharmaceutical Industries Ltd

  • Pharmaleads SA

  • Pharmnovo AB

  • Pherin Pharmaceuticals Inc

  • Promius Pharma LLC

  • Pulmatrix Inc

  • Qingdao Chia Tai Haier Pharmaceutical Co Ltd

  • RAFT Pharmaceuticals

  • Revance Therapeutics Inc

  • Satsuma Pharmaceuticals Inc

  • Seurat Therapeutics Inc

  • Shanghai Junshi Bioscience Co Ltd

  • Shin Nippon Biomedical Laboratories Ltd

  • Sorrento Therapeutics Inc

  • Sosei Heptares

  • Suda Pharmaceuticals Ltd

  • Teva Pharmaceutical Industries Ltd

  • Trevena Inc

  • Trigemina Inc

  • TrioxBio Inc

  • United Neuroscience Ltd

  • Xenon Pharmaceuticals Inc

  • Xoc Pharmaceuticals Inc

  • Zosano Pharma Corp

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/u7s9rp

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900